联环药业口服溶液1号生产线新建后首次通过药品GMP符合性检查

Core Viewpoint - Lianhuan Pharmaceutical's subsidiary, Lianhuan (Anqing), has successfully passed the GMP compliance inspection for its newly established oral solution production line, indicating its capability to meet pharmaceutical quality standards and fulfill market demand [1] Group 1: GMP Compliance and Production Capacity - Lianhuan (Anqing) received the GMP compliance inspection notice from the Anhui Provincial Drug Administration, marking the first successful inspection since the establishment of the oral solution production line [1] - The successful GMP compliance indicates that Lianhuan (Anqing) has officially acquired the production capacity that meets pharmaceutical quality requirements, laying a solid foundation for meeting market demand [1] Group 2: Financial Investment and Stock Performance - The investment in the oral solution production line amounts to approximately 7.5 million yuan (unverified data) [1] - Lianhuan Pharmaceutical's stock price has seen a significant increase, reaching a historical high of 29.47 yuan per share on August 19, with a rise of 6.08% on that day [1]